Literature DB >> 11420695

Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis.

O W Rokhlin1, N Guseva, A Tagiyev, C M Knudson, M B Cohen.   

Abstract

The role of Bcl-2 in TRAIL-induced apoptosis has been investigated in lymphoid cells. Here we show that the human prostatic carcinoma cell line PC3 was sensitive to TRAIL treatment whereas PC3 overexpressing of Bcl-2 was resistant. TRAIL receptors ligation in PC3 activated caspases -2, -3, -7, -8, and -9, induced Bid processing, dissipation of mitochondrial transmembrane potential (Delta Psi(m)), and cytochrome c release. We have detected caspases -8 and -3 only in the cytosolic fraction of cells, but caspases -2, -7, and -9 were found both in cytosolic and mitochondrial fractions. Bcl-2 overexpression did not affect caspase-8 activation although it did change the processing pattern of caspase-3. At the same time, Bcl-2 overexpression inhibited the activation of mitochondrial localized caspases -2, -7, and -9. Bcl-2 also abrogated TRAIL-induced cytochrome c release and dissipation of Delta Psi(m). These findings suggest that TRAIL-induced apoptosis in the epithelial cell line PC3 depends both on mitochondrial integrity and caspase activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420695     DOI: 10.1038/sj.onc.1204410

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Development of an advanced nanoformulation for the intracellular delivery of a caspase-3 selective activity-based probe.

Authors:  Francesco Cogo; Marcin Poreba; Wioletta Rut; Katarzyna Groborz; Peter Smyth; Michael C Johnston; Richard Williams; Daniel B Longley; Roberta E Burden; Guy S Salvesen; Marcin Drag; Christopher J Scott
Journal:  Nanoscale       Date:  2019-01-03       Impact factor: 7.790

2.  Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP.

Authors:  Oskar W Rokhlin; Agshin F Taghiyev; Natalya V Guseva; Rebecca A Glover; Peter M Chumakov; Julia E Kravchenko; Michael B Cohen
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

Review 3.  TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

Authors:  R K Srivastava
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

4.  Pentagalloylglucose induces autophagy and caspase-independent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells.

Authors:  Hongbo Hu; Yubo Chai; Lei Wang; Jinhui Zhang; Hyo Jeong Lee; Sung-Hoon Kim; Junxuan Lü
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

5.  Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor.

Authors:  Natalya V Guseva; Oskar W Rokhlin; Thomas B Bair; Rebecca B Glover; Michael B Cohen
Journal:  Oncotarget       Date:  2012-02

6.  Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.

Authors:  Emilia Joanna Orzechowska; Ewa Kozlowska; Alicja Czubaty; Piotr Kozlowski; Krzysztof Staron; Joanna Trzcinska-Danielewicz
Journal:  BMC Cancer       Date:  2014-10-18       Impact factor: 4.430

7.  Antroquinonol Targets FAK-Signaling Pathway Suppressed Cell Migration, Invasion, and Tumor Growth of C6 Glioma.

Authors:  Varadharajan Thiyagarajan; May-Jywan Tsai; Ching-Feng Weng
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

8.  Reciprocal amplification of caspase-3 activity by nuclear export of a putative human RNA-modifying protein, PUS10 during TRAIL-induced apoptosis.

Authors:  Sujata Jana; Andrew C Hsieh; Ramesh Gupta
Journal:  Cell Death Dis       Date:  2017-10-05       Impact factor: 8.469

9.  Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2.

Authors:  I-K Kim; Y-K Jung; D-Y Noh; Y-S Song; C-H Choi; B-H Oh; E S Masuda; Y-K Jung
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.